Clene (NASDAQ:CLNN) is a biopharmaceutical company focused on the development of unique therapies for neurodegenerative diseases. It harnesses nanotechnology to create products aimed at enhancing the cellular energy metabolism, a critical aspect of combating conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's disease. One of its flagship projects is the development of CNM-Au8, an investigational drug designed to improve neuronal survival. Clene's mission revolves around pioneering novel treatments that can significantly alter the course of neurodegenerative illnesses, offering hope and improving the quality of life for patients worldwide. Through ongoing clinical trials and research collaborations, Clene aims to unlock new possibilities in medical science, demonstrating their commitment to innovation and the well-being of individuals facing these challenging diseases.